Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gary Reese

Neurology Scottsdale, AZ Medical Doctor

NPI 1003994534 CMS profile 136464

7242 E. Osborn Road, Suite 400, Scottsdale, AZ 85251

Open in the dashboard

General payments

$10,336

235 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gary Reese of Scottsdale, AZ is reported in the CMS Open Payments database as having received $10,336 across 235 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $489 7
2024 General $172 4
2023 General $723 6
2022 General $334 9
2021 General $844 44
2020 General $5,630 58
2019 General $2,145 107

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Reese
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Gary Reese were reported at $489. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Gary Reese Neurology median Middle half National median
2019 $2,145 $474 $118–$2,177 $163
2020 $5,630 $367 $82–$2,309 $114
2021 $844 $438 $104–$2,547 $132
2022 $334 $442 $103–$2,388 $149
2023 $723 $464 $119–$2,312 $160
2024 $172 $468 $119–$2,323 $164
2025 $489 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $6,237 44 payments
  2. Novartis Pharmaceuticals Corporation $698 31 payments
  3. UCB, Inc. $557 72 payments
  4. Idorsia Pharmaceuticals US Inc $455 3 payments
  5. Amgen Inc. $420 13 payments
  6. EMD Serono, Inc. $399 22 payments
  7. Alexion Pharmaceuticals, Inc. $304 5 payments
  8. AbbVie, Inc. $157 8 payments
  9. Acorda Therapeutics, Inc $149 5 payments
  10. SK Life Science, Inc. $146 9 payments
  11. Other $815 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,817 220 payments
  2. Consulting Fee $4,338 5 payments
  3. Travel and Lodging $1,008 4 payments
  4. Education $119 2 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $54 4 payments
Products named General payments · program years 2019–2025
  1. TYSABRI $1,173 26 payments
  2. QUVIVIQ $455 3 payments
  3. MAYZENT $442 14 payments
  4. AIMOVIG $435 15 payments
  5. Briviact $324 39 payments
  6. VUMERITY $300 15 payments
  7. ULTOMIRIS $273 3 payments
  8. KESIMPTA $226 12 payments
  9. Neupro $216 31 payments
  10. Mavenclad $202 14 payments
  11. Other $1,645 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

2,180

Median for Neurology: 833

Drug cost

$256,542

Median for Neurology: $202,670

Branded share of claims

30.3%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aimovig Autoinjector Erenumab-Aooe Brand 47 $42,228
Briviact Brivaracetam Brand 25 $37,555
Nourianz Istradefylline Brand 14 $36,269
Nurtec Odt Rimegepant Sulfate Brand 27 $29,560
Ajovy Autoinjector Fremanezumab-Vfrm Brand 20 $25,051
Ubrelvy Ubrogepant Brand 12 $17,336
Carbidopa-Levodopa-Entacapone Carbidopa/Levodopa/Entacapone Brand 25 $8,207
Galantamine Er Galantamine Hbr Brand 64 $6,481
Carbidopa-Levodopa Carbidopa/Levodopa Brand 221 $5,537
Levetiracetam Generic 99 $5,199

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$67,989

Medicare's payments for the services billed

Medicare patients

571

Average age 77

Services billed

960

294 women, 277 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 34%
Depression 33%
Chronic kidney disease 28%
Atrial fibrillation 24%
Diabetes 22%
Alzheimer's or dementia 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $119
$119 — —
VYALEV
  • AbbVie, Inc. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

235 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record